The stakes could hardly be higher. According to the review, led by Olabisi Tajudeen Obafemi of the University of South Africa and colleagues, the global number of people living with diabetes surged from 200 million in 1990 to 830 million in 2022. Type 2 diabetes accounts for roughly 90 to 95 percent of those cases and is defined by insulin resistance paired with an insufficient compensatory surge of insulin. Persistent high blood glucose progressively damages the vascular, renal, neurological, ocular and cardiovascular systems, generating enormous morbidity and healthcare expenditure. Current drugs, including sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, mostly manage glucose downstream of the underlying cellular damage.

The authors contend that upstream stress-response pathways deserve far more therapeutic attention because they lie closer to the molecular origins of the disease. Among these, the IRE1α/XBP1 arm of the UPR is the most evolutionarily conserved, meaning that findings in model organisms often translate more readily to human biology. IRE1α is a transmembrane protein with a stress-sensing domain inside the ER lumen and kinase plus endoribonuclease (RNase) domains facing the cytoplasm. Under resting conditions, the chaperone GRP78, also known as BiP, keeps IRE1α inactive. When misfolded proteins accumulate, GRP78 detaches to handle them, allowing IRE1α to oligomerize and trans-autophosphorylate, thereby switching on its RNase domain.

That RNase activity performs one of the most remarkable feats in molecular biology: the unconventional splicing of X-box binding protein 1 (XBP1) mRNA. IRE1α excises a 26-nucleotide intron from XBP1 mRNA in the cytoplasm, producing a frameshift that generates the spliced transcription factor XBP1s. Once in the nucleus, XBP1s switches on genes for ER-associated protein folding, quality control, ER expansion, lipid biosynthesis and enhanced secretory capacity. In its adaptive mode, the pathway is a lifeline, expanding the cell’s folding factory to meet demand. But when ER stress becomes chronic, the same machinery turns destructive, engaging regulated IRE1-dependent decay (RIDD), which degrades essential transcripts, and recruiting inflammatory stress kinases.

The review details how this dual personality plays out across metabolically active tissues. In the liver, XBP1s suppresses gluconeogenesis by promoting the degradation of the transcription factor FOXO1, improving glucose tolerance, while fasting signals phosphorylate hepatic IRE1α at serine 724 to enhance gluconeogenic genes independently of XBP1s. In adipose tissue, XBP1s maintains adipocyte differentiation through the C/EBP family of transcription factors. In pancreatic beta cells, glucose-induced XBP1 splicing expands the machinery needed for proinsulin folding and secretion while limiting oxidative stress; beta-cell-specific XBP1 deficiency reduces insulin granules and weakens glucose-stimulated insulin secretion. Even skeletal muscle uses the pathway adaptively after injury to support regeneration.

Trouble begins when glucotoxicity and lipotoxicity sustain IRE1α signaling beyond its adaptive window. Chronic hyperglycemia hyperactivates IRE1α in beta cells, suppressing insulin gene expression and degrading insulin mRNA through RIDD, converting a protective response into secretory failure. Meanwhile, IRE1α recruits the adaptor protein TRAF2 and activates c-Jun N-terminal kinase (JNK), which phosphorylates insulin receptor substrate-1 on inhibitory serine residues. This blocks downstream PI3K/AKT signaling, reduces GLUT4-mediated glucose uptake and drives systemic insulin resistance. In skeletal muscle, XBP1 and ATF6 upregulate the phosphatase SKIP, further attenuating insulin-stimulated glucose uptake. The result is a feed-forward loop: excess nutrients fuel ER stress, stress kinases blunt insulin action, insulin resistance increases beta-cell workload, and the extra biosynthetic burden deepens ER stress.

The inflammatory consequences may be the most striking. The review describes how hyperactivated IRE1α lowers levels of microRNA-17, which normally represses thioredoxin-interacting protein (TXNIP). Stabilized TXNIP mRNA then promotes activation of the NLRP3 inflammasome, triggering caspase-1-mediated maturation of the inflammatory cytokines IL-1β and IL-18. IRE1α/TRAF2 signaling also activates NF-κB, elevating TNF-α, IL-6 and IL-1β and sustaining the low-grade metabolic inflammation that characterizes obesity and T2DM. The pathway even intersects oxidative stress signaling: acute oxidative stress induces IRE1α sulfenylation and activates an IRE1α–p38–NRF2 antioxidant axis, while in diabetic nephropathy a persistent XBP1–HRD1 axis ubiquitinates NRF2 and strips away renal antioxidant protection.

What elevates the review beyond mechanism is its synthesis of preclinical pharmacology on both sides of the pathway. On the activation side, the small molecule IXA4 selectively boosted adaptive IRE1/XBP1s signaling in diet-induced obese mice, reprogramming the hepatic transcriptome to reduce glucose production and steatosis without triggering RIDD. A successor compound, IXA62, extended activity to kidney and lung and increased glucose-stimulated insulin release. Modest hepatic XBP1s overexpression improved hyperglycemia in insulin-resistant mice partly through FOXO1 degradation, and p38-mediated enhancement of XBP1s activity restored euglycemia in severely obese diabetic mice. In adipose tissue, XBP1s overexpression promoted high-molecular-weight adiponectin multimerization and improved insulin sensitivity in lean and ob/ob mice.

On the inhibition side, kinase-inhibiting RNase attenuators (KIRAs) dampen the maladaptive outputs of IRE1α. In mice lacking Bax inhibitor-1, an endogenous negative regulator of IRE1α, excessive RNase activity drove NLRP3 inflammasome activation, beta-cell death and hyperglycemia; the RNase inhibitor STF-083010 reversed beta-cell failure and normalized the metabolic phenotype, and in obese mice it improved glucose tolerance while suppressing inflammatory adipose-tissue macrophages. More recently, KIRA8 restored sphingosine-1-phosphate lyase activity, improved AKT phosphorylation and glucose uptake in muscle cells, and ameliorated glucose metabolism in high-fat-diet-fed animals. Even a pomegranate flower polyphenol extract showed antidiabetic effects linked to inhibition of the hepatic IRE1α–XBP1–CHOP stress axis.

The authors are careful to stress that the pathway’s intrinsic bidirectionality creates a narrow therapeutic window: success will demand tissue-, dose-, duration- and output-selective modulation rather than blanket activation or suppression. Key unanswered questions include the stage-specific thresholds separating adaptive from harmful signaling, head-to-head comparisons of XBP1s activators, RNase inhibitors and kinase-domain modulators in the same models, and how well animal findings extrapolate to human disease. Still, the strategic position of IRE1α/XBP1 at the intersection of ER proteostasis, insulin signaling, inflammation, oxidative stress and beta-cell survival makes it, in the reviewers’ assessment, a credible next-generation target, one that could intervene where diabetes begins rather than merely where its symptoms end.

Subject of Research: The role of the IRE1α/XBP1 unfolded protein response pathway in type 2 diabetes and its potential as a therapeutic target

Article Title: Targeting the IRE1α/XBP1 pathway in type 2 diabetes mellitus: from ER stress signaling to therapeutic opportunity

Article References: Obafemi, O. T., Ayeleso, A. O., Ekundayo, B. E., Obafemi, B. A., Adewale, O. B., Lebelo, S. L., & Ntwasa, M. (2026). Targeting the IRE1α/XBP1 pathway in type 2 diabetes mellitus: from ER stress signaling to therapeutic opportunity. Molecular Biology Reports, 53(1), Article 1688. https://doi.org/10.1007/s11033-026-12876-7

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12876-7

Keywords: IRE1α, XBP1, unfolded protein response, endoplasmic reticulum stress, type 2 diabetes, insulin resistance, pancreatic beta cells, JNK signaling, NLRP3 inflammasome, RIDD, drug targets, metabolic disease

Pigs were chosen deliberately. As a biomedical model, swine share striking anatomical and metabolic similarities with humans, particularly in cardiovascular physiology, body fat distribution, and digestive function. Human diet studies are notoriously difficult to control, because participants cheat, under-report, and vary wildly in adherence. Fifteen post-pubertal, non-pregnant, non-lactating gilts, Landrace by Yorkshire crosses averaging around 170 kilograms, were individually penned and paired by weight before being randomly assigned to one of two diets. Seven animals received a conventional, nutrient-balanced maintenance ration built around corn, while eight received a low-carbohydrate, high-fat formulation in which beef tallow supplied the energy normally delivered by grain. Soybean hulls were added to the high-fat diet to match the physical consistency of the control ration, and both diets were formulated to meet National Research Council requirements for swine of this age, sex, and reproductive stage.

The laboratory analysis confirmed the diets differed dramatically. The control diet contained roughly 3.3 percent crude fat and nearly 69 percent non-fiber carbohydrate on a dry matter basis, while the experimental diet contained 22.5 percent crude fat and only about 15.6 percent non-fiber carbohydrate, with neutral detergent fiber soaring to more than 44 percent thanks to the soy hulls. Interestingly, the calculated gross energy of the two rations diverged: the control diet provided approximately 3,993 kilocalories per kilogram, while the high-fat formulation came in at 3,448 kilocalories per kilogram, a discrepancy the authors attribute largely to the indigestible fiber fraction used to dilute the diet. Both rations were fed daily at 1.75 percent of each animal’s body weight, and feed refusals were weighed to calculate actual intake.

The results on body composition were the study’s most eye-catching finding. Control gilts gained weight steadily across the trial, ending roughly seven percent heavier than they started, while the high-fat group maintained a nearly constant body weight throughout. More striking was what happened beneath the skin. Measured by ultrasound adjacent the tenth thoracic vertebra, subcutaneous fat depth fell by 17.7 percent in the high-fat animals over 32 days, while control animals showed a 14 percent increase. At slaughter, the differences inside the body were even more dramatic: control gilts carried 1.74 times more visceral fat, the metabolically dangerous internal belly fat, than their high-fat counterparts, 2,660 grams versus 1,440 grams on average. Crucially, the high-fat animals did not waste away; they simply stopped depositing fat while presumably continuing to build lean tissue, an outcome the researchers interpret as a favorable shift in the ratio of muscle to fat.

Appetite appears to have played a central role. Although both groups were offered the same amount of feed relative to body weight, the high-fat gilts consumed significantly less, averaging 2.36 kilograms per day between days 19 and 32 compared with 3.09 kilograms in the control group. Calculated energy intake told the same story, with the control animals consuming more than 12,300 kilocalories daily against roughly 8,150 for the high-fat group. The authors suggest the animals reached satiety sooner and stopped eating, consistent with human trials reporting appetite suppression on ketogenic diets. They also caution, however, that the enormous soy hull load in the experimental diet may have contributed to early fullness or restricted digestible energy, a confound that future work should disentangle by examining fiber and fat effects on total tract digestibility directly.

Blood chemistry offered reassurance on one of the diet’s most feared risks: acidosis. Blood pH did not differ between treatments, and fasted values for sodium, bicarbonate, and carbon dioxide remained within normal reference ranges, indicating that four weeks on the high-fat regimen did not disrupt acid-base homeostasis. Urine ketone testing revealed that nutritional ketosis was largely absent, with no detectable ketones in the third week and only trace amounts, about 5 milligrams per deciliter, in three animals during the fourth. Yet the body composition changes occurred anyway, suggesting a metabolic shift away from fat storage that operated independently of measurable ketosis. One unexpected trend did emerge: fasting glucose in the high-fat group crept upward over the trial, ending significantly higher than controls at day 32, a pattern the authors tentatively link to early keto-adaptation and the liver’s efforts to protect glycogen reserves when adequate dietary protein fuels gluconeogenesis.

The microscopic analysis of the pancreas produced perhaps the most provocative data. Using immunofluorescent staining for insulin on formalin-fixed tissue sections, the researchers found that the percentage of active beta cells in the high-fat group was 2.81 times greater than in controls, 90.7 percent versus 42.4 percent, and that the area occupied by beta cells within the pancreatic islets was 1.81 times larger. Islet area as a percentage of total pancreatic tissue was also more than doubled. These findings suggest an enhancement of pancreatic architecture and insulin-producing capacity, which stands in contrast to earlier rodent studies reporting that long-term ketogenic diets can shrink beta-cell mass and impair glucose tolerance. The discrepancy may reflect species differences, the short feeding duration, or the moderate degree of ketosis actually achieved.

In skeletal muscle, the story was more selective. The researchers quantified insulin receptor presence by measuring the relative fluorescence intensity of antibody-labeled receptor proteins in cross-sections of the longissimus thoracis, the semimembranosus, and the kidney. Only the semimembranosus, a powerful muscle of locomotion in the hind limb, showed a statistically significant increase in insulin receptor density in the high-fed animals, with relative intensity of 32.8 versus 21.7 in controls. The longissimus showed a numerical but non-significant rise, and the kidney showed no difference. The authors propose that upregulated insulin receptors on muscle fibers may contribute to a muscle-sparing effect, supporting the anabolic influence of insulin on myofibrillar protein synthesis while ketone bodies spare amino acids from being diverted into gluconeogenesis. Notably, proximate analysis found no difference in crude fat content of the liver or longissimus muscle between groups, and although the high-fat animals had heavier livers relative to body weight, there was no biochemical indication of early fatty liver disease.

The researchers are candid about their limitations. The trial used only one sex, mature females, because intact males were unavailable and castrated males are considered irrelevant to human medicine, restricting generalizations to women. The ex vivo tissue analyses relied on just three biological replicates per group, and the 32-day feeding period is short by dietary-intervention standards; some human evidence suggests full metabolic benefits of ketogenic adherence may require twelve weeks or more. Statistical tendencies, including the glucose trajectory and the energy balance calculation, should be viewed with caution given the small sample size. Still, the authors argue the data provide preliminary justification for pursuing the metabolic impact of low-carbohydrate, high-fat diets on obesity using swine as a model, particularly the observation that animals lost fat mass without losing body weight.

For the millions of people experimenting with ketogenic eating, the study offers a cautiously encouraging signal wrapped in important caveats. In a tightly controlled animal model, replacing carbohydrate energy with animal fat reduced the most harmful fat depots, preserved body weight, enhanced markers of pancreatic insulin-producing capacity, and increased insulin receptor expression in a major locomotor muscle, all without measurable ketosis and without disturbing blood chemistry. Whether the same remodeling occurs in humans over months and years, and whether the fiber dilution that accompanied the high-fat ration contributed to the appetite effects, remains to be determined. What the pig study demonstrates is that the diet’s effects on body composition and insulin biology are real, measurable at the tissue level, and more nuanced than the popular narrative of ketosis alone would suggest.

Subject of Research: Effects of a low-carbohydrate, high-fat diet on muscle insulin receptor concentration and body composition in a swine biomedical model

Article Title: Does a low‐carb, high‐fat diet change muscle insulin receptor concentration and body composition in a swine biomedical model?

Article References: Acosta‐Castellanos, N., Tiede, S., Byrd, C. J., Borowicz, P., Young, J. M., & Berg, E. P. (2026). Does a low‐carb, high‐fat diet change muscle insulin receptor concentration and body composition in a swine biomedical model?. Physiological Reports, 14(19), Article e71124. https://doi.org/10.14814/phy2.71124

Image Credits: AI Generated

DOI: 10.14814/phy2.71124

Keywords: ketogenic diet, low-carbohydrate high-fat diet, insulin receptor, body composition, swine model, pancreatic beta cells, visceral fat, beef tallow, nutritional ketosis, skeletal muscle, metabolism, Physiological Reports

The molecular logic of insulin resistance begins at the cell membrane. When insulin binds its receptor, a signalling cascade follows: insulin receptor substrates are tyrosine-phosphorylated, the PI3K/Akt pathway is activated, and the glucose transporter GLUT4 moves to the cell surface to import glucose. In resistant tissues, this cascade is sabotaged. Stress kinases such as JNK and PKC drive excessive serine phosphorylation of insulin receptor substrates, blunting the signal, while negative regulators like PTEN and SOCS proteins and inflammatory cytokines such as TNF-alpha and IL-6 further suppress the pathway. Meanwhile, diacylglycerols and ceramides accumulate in non-adipose tissues, creating a lipotoxic environment that fuels endoplasmic reticulum stress and oxidative damage. In adipose tissue, macrophages polarize toward a pro-inflammatory M1 state, adiponectin secretion falls, and leptin and resistin rise, amplifying systemic resistance.

What makes the review’s argument distinctive is its emphasis on mitochondria as central players rather than bystanders. Mitochondria govern substrate oxidation, ATP synthesis, and reactive oxygen species homeostasis, and in insulin-resistant skeletal muscle their oxidative capacity consistently declines. Impaired fatty acid oxidation allows partially oxidized lipid intermediates to build up, and these metabolites actively sabotage insulin signalling through PKC and JNK activation. In the liver, mitochondrial dysfunction promotes pathological gluconeogenesis and fat accumulation, while in pancreatic beta cells it accelerates stress-induced apoptosis. The review describes a self-reinforcing loop in which disrupted fusion and fission dynamics, stalled mitophagy, and downregulated biogenesis through the PGC-1alpha/NRF1/TFAM axis drive ROS overproduction and ATP depletion, deepening signalling defects and eventually precipitating beta-cell failure.

Against this backdrop, mesenchymal stem cell-derived exosomes have emerged as a compelling cell-free therapeutic platform. These membrane-bound nanovesicles, roughly 30 to 150 nanometres across, are generated through the endosomal pathway and carry a heterogeneous cargo of microRNAs, long non-coding RNAs, proteins, lipids, and metabolites. They display characteristic surface markers such as the tetraspanins CD9, CD63, and CD81 along with TSG101 and ALIX, and their cholesterol- and sphingomyelin-rich membrane supports vesicle stability. Once taken up by recipient cells through endocytosis or membrane fusion, this cargo can reprogramme gene expression and cellular behaviour. Crucially, compared with transplanting whole stem cells, exosomes carry negligible risk of tumorigenicity or ectopic differentiation, provoke low immunogenicity, can be stored and standardized as off-the-shelf biologics, and can cross barriers as formidable as the blood-brain barrier.

The preclinical evidence base is growing rapidly. Exosomes from human umbilical cord mesenchymal stem cells administered to diabetic rats increased GLUT4 translocation, lowered HbA1c, and improved glucose uptake, while in insulin-resistant human adipocytes they restored glucose uptake by upregulating SIRT1 and IRS1 and normalizing adipokine profiles, decreasing leptin and raising adiponectin. Bone marrow-derived exosomes activated the PI3K/Akt pathway, increased GLUT4 expression, and shifted adipose tissue macrophages toward an anti-inflammatory M2 phenotype in diet-induced obese mice. Wharton’s jelly-derived exosomes alleviated hepatic steatosis by activating the FGF21/adiponectin axis, reducing endoplasmic reticulum stress, and enhancing mitochondrial fatty acid oxidation. Other studies showed reduced beta-cell apoptosis and improved insulin secretion in diabetic rat models. The review is candid, however, that most of these findings come from short-term rodent studies with small sample sizes and considerable heterogeneity in exosome sources, isolation methods, and dosing.

The microRNA cargo is where the therapeutic precision lies. These roughly 22-nucleotide non-coding RNAs fine-tune gene expression post-transcriptionally, and several are deeply implicated in insulin resistance. The review highlights miR-29b-3p as a cautionary tale: exosomes from aged bone marrow stem cells are enriched in this microRNA, which targets SIRT1 and actively promotes metabolic dysfunction, and inhibiting it rescues insulin sensitivity, implicating it in age-related resistance. By contrast, miR-21 protects pancreatic beta cells under hypoxic and inflammatory stress by suppressing pro-apoptotic pathways involving p38 MAPK, PDCD4, and FasL, while miR-146a dampens NF-kappaB signalling and reduces secretion of TNF-alpha, IL-6, and IL-1beta. An insulin-sensitizing microRNA called miR-3075, enriched in hepatocyte-derived exosomes during early-stage obesity, enhances insulin sensitivity by targeting fatty acid 2-hydroxylase, though this compensatory mechanism is lost in chronic obesity.

This is precisely where genetic engineering enters the picture. Rather than relying on whatever cargo native exosomes happen to carry, researchers can reprogramme the parent stem cells using lentiviral transfection or electroporation, enriching the resulting vesicles with protective microRNAs while silencing harmful ones such as miR-29b-3p through antagonists, siRNAs, or CRISPR interference. Bicistronic and multi-cistronic vectors built with internal ribosome entry sites or 2A self-cleaving peptides allow a single exosome to carry combinations such as miR-21, miR-146a, and SIRT3, a mitochondrial deacetylase that enhances respiratory chain function, curbs ROS production, and promotes PGC-1alpha-mediated biogenesis via SOD2. Dual-engineered exosomes co-loading SIRT3 with insulin-mimetic domains have already shown superior mitochondrial protection in myocardial ischemia-reperfusion models, and analogous strategies could, in principle, reverse the bioenergetic deficits that characterize insulin-resistant muscle, liver, and islets.

Targeting is the other half of the engineering challenge. Because insulin resistance is a systemic, multi-organ disease, exosomes must reach skeletal muscle, adipose tissue, the liver, and pancreatic islets simultaneously, yet biodistribution studies show that systemically injected vesicles are rapidly cleared by the liver and spleen. Surface functionalization offers partial answers: polyethylene glycol prolongs circulation, while conjugated homing peptides, aptamers, and antibodies steer vesicles toward specific organs. The review cites examples including dual-engineered vesicles co-expressing CXCR4 and a P-selectin-binding peptide for tissue-specific homing, aptamer-functionalized exosomes that suppressed allergic airway inflammation in mice, and an ASGR1-targeting platform designed to home to hepatocytes for fatty liver disease. Aptamer- and PEG-modified exosomes have shown superior islet protection compared with unmodified vesicles, combining prolonged circulation with precise beta-cell delivery.

Substantial hurdles remain before any of this reaches patients. Manufacturing is a bottleneck: ultracentrifugation, tangential flow filtration, and size-exclusion chromatography each compromise reproducibility, and genetic modification adds variability in transfection efficiency and cargo loading. Viral vectors raise concerns about insertional mutagenesis and long-term oncogenic potential, while the long-term safety of repeated dosing and of overexpressed agents like SIRT3 is untested. Mechanistically, much of the evidence remains correlative, and direct transfer of intact mitochondria via exosomes is still debated, with most data favouring miRNA- and protein-mediated regulation instead. As of 2025, exosome therapies have entered early-phase trials mainly for wound healing, graft-versus-host disease, and diabetic complications, but no large-scale trial has yet targeted systemic insulin resistance.

Even so, the conceptual shift the review describes is hard to ignore. Conventional drugs such as metformin and thiazolidinediones modestly improve insulin sensitivity but cannot simultaneously correct impaired signalling, chronic inflammation, ectopic lipid burden, and mitochondrial dysfunction. Gene-modified exosomes, by contrast, are designed to do all of these things in one particle, coordinating signalling restoration, inflammatory repolarization, beta-cell preservation, and mitochondrial rescue. If the field can solve scalable good-manufacturing-practice production, achieve durable multi-organ targeting, and validate safety in large animal models, these engineered nanovesicles could move from experimental tools to genuine disease-modifying therapies, transforming the treatment of insulin resistance from symptom management into root-cause repair.

Subject of Research: Gene-modified mesenchymal stem cell-derived exosomes as a therapeutic strategy for insulin resistance

Article Title: Therapeutic Potential of Gene‐Modified MSC‐Exos in Insulin Resistance: Mitochondrial Crosstalk and miRNA Regulation

Article References: Jia, Q., Li, B., Xing, Y., Zhang, Y., Gao, B., Li, X., & Ha, X. (2026). Therapeutic Potential of Gene‐Modified MSC ‐Exos in Insulin Resistance: Mitochondrial Crosstalk and miRNA Regulation. Journal of Cellular and Molecular Medicine, 30(17), Article e71342. https://doi.org/10.1111/jcmm.71342

Image Credits: AI Generated

DOI: 10.1111/jcmm.71342

Keywords: insulin resistance, MSC-derived exosomes, mesenchymal stem cells, miRNA, mitochondrial dysfunction, type 2 diabetes, SIRT3, gene engineering, exosome therapy, metabolic disease, inflammation, pancreatic beta cells

The starting point of the commentary is a deceptively simple set of numbers. Beta cells proliferate slowly compared with most other cell types. In rodents, the replication rate ranges from roughly one to two percent per day. In humans it is an order of magnitude lower, somewhere between 0.1 and 0.2 percent per day. The rate is higher in children and adolescents than in adults, because during physical growth the beta-cell mass must expand in parallel with increasing body mass to meet the rising demand for insulin. Once adulthood is reached, however, the proliferative machinery is dialed down to a near-idle pace.

That near-idle pace is not, in itself, a design flaw. During the neonatal phase and early childhood, the formation of new beta cells from progenitor cells plays a central role in expanding the beta-cell mass. In adulthood, by contrast, new beta cells arise almost exclusively through the self-duplication of existing ones. Although this rate is very low, it is not zero, and crucially it appears to be sufficient. The trickle of new cells compensates for losses caused by apoptotic beta-cell death, thereby maintaining a stable functional population across decades of life. Beta cells, in other words, retain a degree of plasticity even in the mature pancreas, but that plasticity operates within narrow limits.

Lenzen emphasizes that the organism appears to possess an internal set point for functional beta-cell mass, and that this set point serves a protective purpose. Insulin is a potentially lethal molecule when present in excess, and unregulated expansion of the beta-cell population would risk fatal hypoglycemia. The clearest demonstration of the dangers of losing this regulatory control is persistent hyperinsulinemic hypoglycemia of infancy, a congenital disorder in which the genetically determined regulation of functional beta-cell mass fails, leading to life-threatening overproduction of insulin. Far from being a limitation to be overcome, the slow proliferation rate reflects an evolved compromise between metabolic safety and repair capacity.

The set point is not fixed in stone, however. Beta-cell mass is subject to complex hormonal regulation that operates across the mammalian kingdom, including in humans. Thyroid hormones reduce beta-cell mass by promoting apoptosis, while glucocorticoids increase it by stimulating proliferation. The well-documented expansion of beta-cell mass during pregnancy provides another striking example of physiologically orchestrated adaptation. In each case, the endocrine system adjusts the size of the insulin-producing cell pool to match anticipated metabolic demand, and understanding these regulatory levers has become a central goal of diabetes research.

The relevance to disease becomes apparent when one traces what happens to beta-cell mass over a lifetime in the context of modern lifestyles. In many adults, beta-cell mass increases by up to 50 percent between the third and fifth decades of life, coinciding with the development of obesity during this period. This expansion is driven by increasing insulin resistance associated with a Western diet and lifestyle, and the accompanying rise in insulin production. Only a minority of individuals, no more than 20 percent, are able to maintain this elevated beta-cell mass and the resulting adequate insulin supply into old age despite ongoing obesity. The vast majority cannot. In most people, a gradual decline in beta-cell mass follows this phase of life, leading to insulin deficiency and ultimately to the development of type 2 diabetes. The proliferative capacity of beta cells therefore matters in two ways: it can counteract the deterioration of metabolic state during the pre-diabetic phase, and it may support efforts to restore metabolic control after diabetes onset. At the same time, any increased workload on beta cells, whether caused by obesity or autoimmune attack, carries the risk of deteriorating beta-cell function and shrinking beta-cell mass, so reducing that workload is itself a therapeutic priority.

Hormones capable of increasing beta-cell mass have consequently moved to the forefront of scientific interest, and none more so than the gut hormone glucagon-like peptide-1, or GLP-1. A recent study by Erbasan and colleagues, published in the same journal, has provided compelling new evidence for the regenerative potential of this incretin hormone. Using gene therapy in neonatal and adult streptozotocin-diabetic rats, the researchers achieved GLP-1 release through lentivirally mediated overexpression of the hormone in hepatocytes. The result was support for pancreatic beta-cell regeneration, but with a crucial developmental twist. In the neonatal pancreas, plasticity was high, and beta-cell neogenesis from progenitor and duct-derived cells was evident. In the adult pancreas, new beta cells were generated mainly through self-duplication of existing cells, confirming earlier landmark observations, with only limited potential for neogenesis and consequently for recovery of beta-cell mass.

The implications for therapy are direct. GLP-1-based treatment represents a future option for counteracting the insulin deficiency that develops gradually during the course of type 2 diabetes as beta cells progressively fail. Ideally, Lenzen argues, such intervention should occur before metabolic deterioration sets in, when supporting endogenous proliferation can preserve beta-cell mass most effectively. Treatment with a GLP-1 analogue would offer a double benefit in this window: it would support the preservation of beta-cell mass while simultaneously promoting weight loss, thereby easing the insulin resistance that drives the excessive workload on the remaining cells in the first place.

Type 1 diabetes presents an even more formidable challenge, because the beta-cell loss is driven by autoimmune destruction rather than metabolic overload. More than 90 percent of patients who develop type 1 diabetes have no family history of the disease, which means almost all individuals are diagnosed only when they manifest overt disease at stage 3, by which point much of the beta-cell mass has already been destroyed. Interestingly, however, in the weeks following disease onset, most patients enter a remission phase while receiving insulin replacement therapy, during which the remaining beta cells recover. It is during this phase, ideally after beta-cell recovery but before the onset of renewed metabolic deterioration, that the chances of achieving a significant increase in beta-cell mass through self-duplication are optimal. Seizing this window requires therapies with curative potential, and because numerous monotherapies have proven ineffective, only combination therapies based on a profound understanding of the underlying pathomechanisms and validated in reliable preclinical animal studies are considered promising candidates. A critical constraint is that successful combination therapies for type 1 diabetes require the presence of at least 30 percent of normal beta-cell mass at the start of treatment.

The arithmetic of regeneration underscores why timing is everything. Based on generally accepted beta-cell proliferation rates of one percent per day in rats and 0.1 percent per day in humans, Lenzen calculates that after a cessation of autoimmune-mediated beta-cell destruction, approximately two months are required in rats to increase beta-cell mass from one-third to two-thirds of the original healthy mass, a prediction that aligns with experimental results from animal models. By analogy, the same increase in humans would take one to two years. Encouragingly, a recent medical case study found that a combination of the two therapeutic antibodies teplizumab and adalimumab proved effective in patients, resulting in sustained metabolic health one year after the start of therapy, with no symptoms of diabetes and no need for insulin replacement. Yet the sequencing matters profoundly. Only after successfully suppressing the autoimmune destruction driven by the proinflammatory cytokines TNF-alpha and IL-1 beta, and eliminating the immune-cell infiltration within the islets, does the administration of an agent such as a GLP-1 analogue become a viable option to enhance spontaneous beta-cell regeneration. This approach is particularly suitable when beta-cell mass is already significantly reduced below 50 percent, as it provides supplementary support for proliferation. Administering the agent earlier, while the autoimmune attack is still ongoing, would merely result in the immediate destruction of the newly formed beta cells; studies in animal models have shown that during an ongoing autoimmune attack, proliferation does attempt to counteract beta-cell loss but ultimately fails.

The overarching message is one of calibrated optimism. Despite the different pathomechanisms responsible for beta-cell loss in type 1 and type 2 diabetes, distinct windows of opportunity exist for therapeutic interventions at appropriate stages of both diseases. In type 2 diabetes, that window opens in the pre-diabetic phase, when GLP-1-based therapy can preserve and support an expanded beta-cell mass before it collapses under the combined burdens of insulin resistance and age-related proliferative decline. In type 1 diabetes, the window opens after autoimmune destruction has been halted and the remaining beta cells have begun to recover, when regenerative support can rebuild a functional cell population from the residual base. In both cases, the prospect of supporting endogenous mechanisms for increasing beta-cell mass through beta-cytotrophic molecules offers a pathway that works with the body’s own biology rather than against it. The slow pace of beta-cell renewal, once viewed primarily as an obstacle, is now understood as the defining constraint that any curative strategy must respect, and the therapies that succeed will be those that arrive at precisely the right moment in the disease course.

Subject of Research: Regulation of pancreatic beta-cell mass and its implications for antidiabetic therapies

Article Title: Regulation of pancreatic beta-cell mass and its importance for antidiabetic therapies

Article References: Regulation of pancreatic beta-cell mass and its importance for antidiabetic therapies. (n.d.). https://doi.org/10.1007/s00109-026-02716-3

Image Credits: AI Generated

DOI: 10.1007/s00109-026-02716-3

Keywords: pancreatic beta cells, beta-cell mass, diabetes, type 1 diabetes, type 2 diabetes, GLP-1, beta-cell proliferation, insulin, autoimmunity, gene therapy, teplizumab, endocrinology